Eni and its partners have successfully launched the hull of the Coral North FLNG facility, marking a key step forward in the development of Mozambique’s offshore natural gas resources. The project, ...

Henkel has agreed to acquire ATP Adhesive Systems, a leading specialist in high-performance water-based specialty tapes, to further strengthen its Adhesive Technologies business and expand beyond ...

The Kansas City Chiefs’ 2025 season has unraveled on multiple fronts. After years of sustained success, the Chiefs were eliminated from playoff contention following a Week 15 loss to the Los Angeles ...

Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate SIM0613 is optimally designed ...

A newly discovered security flaw in the React ecosystem — one of the most widely used technologies on the web — is prompting urgent warnings across the tech industry. The bug — dubbed “React2Shell” — ...

Exchange at Indian Trail in Indian Trail, N.C. was one of the three properties refinanced in this portfolio, receiving $56.2 million. Image courtesy of Hathaway Development Hathaway Development ...

Modon joins a consortium of investors to elevate Wellington International equestrian showgrounds and develop an ultra-luxury destination integrating residential, hospitality and sports assets in ...

PATERSON — A Boston-based development company is buying a complex of 88 apartments in Paterson's crime-plagued 4th Ward for $13.7 million and plans to renovate the buildings over the next two years.

Nov 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, aiming to expand its presence in treatments ...

Lexie Hull enters the WNBA offseason after a breakout 2025 campaign. Hull played all 44 games for Indiana amid multiple major injuries on the team’s roster. She hits free agency and is officially set ...

After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity treatment scene has persuaded Zealand Pharma to aim its development engine ...